A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 170 participants.

Also called NCT03449251

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose other
Phase
Phase 2
Enrolled
  • 170 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03449251
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT03449251. Randomized; triple masking; primary purpose other. Start 2018-03-28 (actual); primary completion 2026-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin
Acronym
DEFINE
Condition
Cardiovascular Diseases
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Apelin
Intervention (Drug)
Relaxin
Intervention (Drug)
Normal saline
Intervention (Diagnostic test)
Verapamil
Intervention (Diagnostic test)
LN Monomethyl arginine
Lead sponsor
Cambridge University Hospitals NHS Foundation Trust (class: other)
Collaborator
University of Cambridge (class: other)
Collaborator
AstraZeneca (class: industry)
Collaborator
MedImmune LLC (class: industry)

Record details

Record id
cardio:ct-nct03449251
Content hash
a4947541b75e286aa2879dc4da79d070f35cdb880658031ba009b641d2bec19d